Molecular Medicine, Austrian Institute of Technology, Seibersdorf, Austria.
BMC Cancer. 2010 Nov 16;10:627. doi: 10.1186/1471-2407-10-627.
The simplicity and potential of minimal invasive testing using serum from patients make auto-antibody based biomarkers a very promising tool for use in diagnostics of cancer and auto-immune disease. Although several methods exist for elucidating candidate-protein markers, immobilizing these onto membranes and generating so called macroarrays is of limited use for marker validation. Especially when several hundred samples have to be analysed, microarrays could serve as a good alternative since processing macro membranes is cumbersome and reproducibility of results is moderate.
Candidate markers identified by SEREX (serological identification of antigens by recombinant expression cloning) screenings of brain and lung tumour were used for macroarray and microarray production. For microarray production recombinant proteins were expressed in E. coli by autoinduction and purified His-tag (histidine-tagged) proteins were then used for the production of protein microarrays. Protein arrays were hybridized with the serum samples from brain and lung tumour patients.
Methods for the generation of microarrays were successfully established when using antigens derived from membrane-based selection. Signal patterns obtained by microarrays analysis of brain and lung tumour patients' sera were highly reproducible (R = 0.92-0.96). This provides the technical foundation for diagnostic applications on the basis of auto-antibody patterns. In this limited test set, the assay provided high reproducibility and a broad dynamic range to classify all brain and lung samples correctly.
Protein microarray is an efficient means for auto-antibody-based detection when using SEREX-derived clones expressing antigenic proteins. Protein microarrays are preferred to macroarrays due to the easier handling and the high reproducibility of auto-antibody testing. Especially when using only a few microliters of patient samples protein microarrays are ideally suited for validation of auto-antibody signatures for diagnostic purposes.
利用患者血清进行微创检测的简单性和潜力使得基于自身抗体的生物标志物成为癌症和自身免疫性疾病诊断中非常有前途的工具。虽然已经存在几种用于阐明候选蛋白标志物的方法,但将这些标志物固定在膜上并生成所谓的宏阵列对于标志物验证的用途有限。特别是当需要分析数百个样本时,微阵列可以作为一个很好的替代方案,因为处理宏膜很繁琐,并且结果的重现性中等。
通过脑和肺肿瘤的 SEREX(重组表达克隆的血清学鉴定)筛选鉴定出候选标志物,用于制作宏阵列和微阵列。对于微阵列的制作,通过自动诱导在大肠杆菌中表达重组蛋白,并纯化 His 标记(组氨酸标记)的蛋白,然后用于生产蛋白质微阵列。蛋白质阵列与脑和肺肿瘤患者的血清样本杂交。
当使用基于膜选择的抗原时,成功建立了生成微阵列的方法。脑和肺肿瘤患者血清的微阵列分析获得的信号模式具有高度的可重复性(R = 0.92-0.96)。这为基于自身抗体模式的诊断应用提供了技术基础。在这个有限的测试集中,该检测方法提供了高重复性和广泛的动态范围,能够正确分类所有的脑和肺样本。
当使用表达抗原性蛋白的 SEREX 衍生克隆时,蛋白质微阵列是一种基于自身抗体检测的有效手段。由于自身抗体检测的操作更简单且重现性更高,因此蛋白质微阵列优于宏阵列。特别是当只使用少量患者样本的微升时,蛋白质微阵列非常适合验证自身抗体特征以用于诊断目的。